GD iEXo 002
Alternative Names: GD-iEXo-002; Induced pluripotent stem cell exosome nasal drops - Guidon Pharmaceutics; iPSC-Exos - Guidon PharmaceuticsLatest Information Update: 22 Jun 2023
At a glance
- Originator Guidon Pharmaceutics
- Class Antiepileptic drugs; Exosome therapies
- Mechanism of Action Exosome replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Partial epilepsies
Most Recent Events
- 07 Jun 2023 Guidon Pharmaceutics files an IND application with the regulatory body in China for Epilepsy (Guidon Pharmaceutics website, June 2023)
- 23 May 2023 Phase-0 for Partial epilepsies (Treatment-resistant) in China (Intransal) (NCT05886205)
- 10 Feb 2023 Early research in Partial epilepsies in China (Intransal) prior to February 2023